Did I sign my life away when I signed that offer letter?

All I want to do is talk to a company to see if we can do a deal, why do I need to sign a confidentiality agreement?

All I want to do is consult for a few hours a week, why do I have to sign a consulting agreement and notify my university?

I was told I can’t use the knowledge I gained on my prior job. Isn’t it why they hired me here?

Have you ever found yourself asking questions like these? Whether you are dealing with a “simple” confidentiality agreement, a consulting agreement, or a multi-billion-dollar license, legal provisions are often a source of misunderstanding, confusion and frustration.

This panel, composed of experienced professionals, will help the audience spot important legal issues by providing specific examples of provisions from common types of agreements encountered in the biotech industry, including confidentiality, consulting, material transfer, and employment and separation agreements, that typically lead to problems when not fully understood at the time of negotiation. The interplay of Legal, BD, and R&D perspectives will be discussed.

Speakers:

• Christine P. Bellon, PhD, JD,  VP Legal Affairs,  Blueprint Medicines
• Phil McGurk,  PhD, MBA, Senior Director, R&D Business Development, Pfizer
• Leda Trivinos, PhD, JD, Partner, Intellectual Property, Flagship Ventures

Moderator:

• Mike Biro, PhD, JD, MS, Senior Counsel, CRISPR Therapeutics